(Reuters) – Clovis Oncology Inc said on Friday the U.S. Food and Drug Administration has approved its drug Rubraca for the treatment of adult patients with castration-resistant prostate cancer, whose tumors have a genetic mutation.
The approval is for the drug’s use in patients whose tumors have a mutation called BRCA, and whose disease had advanced despite prior rounds of chemotherapy, the company said.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Shailesh Kuber)
